Analysts noted that they envision "durable growth" in Veracyte's Afirma and Decipher Prostate tests and "long-term growth potential" from its MRD testing business.
The firm's total revenues increased 5 percent year over year, leading it to raise the midpoint of its full-year EPS guidance.
Aspira can now offer the test, intended for assessing ovarian cancer risk in women with an adnexal mass, to patients in New York state.